Preclinical investigation of bioactive substances

Link to this page

info:eu-repo/grantAgreement/MESTD/Integrated and Interdisciplinary Research (IIR or III)/41010/RS//

Preclinical investigation of bioactive substances (en)
Преклиничка испитивања биоактивних супстанци (sr)
Preklinička ispitivanja bioaktivnih supstanci (sr_RS)
Authors

Publications

Antiproliferative and antimigratory effects of 3-(4-substituted benzyl)-5-isopropyl-5-phenylhydantoin derivatives in human breast cancer cells

Obradović, Ana; Matić, Miloš; Ognjanović, Branka; Đurđević, Predrag; Marinković, Emilija; Ušćumlić, Gordana; Božić, Bojan; Božić-Nedeljković, Biljana

(Elsevier, Amsterdam, 2020)

TY  - JOUR
AU  - Obradović, Ana
AU  - Matić, Miloš
AU  - Ognjanović, Branka
AU  - Đurđević, Predrag
AU  - Marinković, Emilija
AU  - Ušćumlić, Gordana
AU  - Božić, Bojan
AU  - Božić-Nedeljković, Biljana
PY  - 2020
UR  - http://intor.torlakinstitut.com/handle/123456789/566
AB  - In this study, a series of synthesized 3-(4-substituted benzyl)-5-isopropyl-5-phenylhydantoin derivatives as a potential antiproliferative and antimigratory agents were investigated. The possible antitumor mechanisms of investigated hydantoin derivatives were examined on human breast cancer cell line MDA-MB-231. The cells were treated with different concentrations of compounds (from 0.01 mu M to 100 mu M) during 24 h and 72 h. The proliferation index, nitric oxide production, apoptosis rate, and migration capacity were measured. The cell invasion potential was examined by measuring the level of MMP-9 and COX-2 gene expression. All tested compounds expressed antiproliferative activity and induced dose- and time-dependent increase in the level of nitrites. The investigated molecules significantly decreased cell survival rate, migration capacity and the expression levels of genes included in the process of tumor invasion. Obtained data suggest that the tested hydantoin derivatives express considerable antitumor activity by reducing cell division rate, elevating apoptosis level, and inhibiting the motility and invasiveness of breast cancer cells. The results obtained in this study indicate that investigated compounds express potential as a novel chemotherapeutic agents against breast cancer growth and progression. (C) 2020 The Author(s). Published by Elsevier B.V. on behalf of King Saud University.
PB  - Elsevier, Amsterdam
T2  - Saudi Pharmaceutical Journal
T1  - Antiproliferative and antimigratory effects of 3-(4-substituted benzyl)-5-isopropyl-5-phenylhydantoin derivatives in human breast cancer cells
EP  - 254
IS  - 3
SP  - 246
VL  - 28
DO  - 10.1016/j.jsps.2020.01.003
UR  - conv_472
ER  - 
@article{
author = "Obradović, Ana and Matić, Miloš and Ognjanović, Branka and Đurđević, Predrag and Marinković, Emilija and Ušćumlić, Gordana and Božić, Bojan and Božić-Nedeljković, Biljana",
year = "2020",
abstract = "In this study, a series of synthesized 3-(4-substituted benzyl)-5-isopropyl-5-phenylhydantoin derivatives as a potential antiproliferative and antimigratory agents were investigated. The possible antitumor mechanisms of investigated hydantoin derivatives were examined on human breast cancer cell line MDA-MB-231. The cells were treated with different concentrations of compounds (from 0.01 mu M to 100 mu M) during 24 h and 72 h. The proliferation index, nitric oxide production, apoptosis rate, and migration capacity were measured. The cell invasion potential was examined by measuring the level of MMP-9 and COX-2 gene expression. All tested compounds expressed antiproliferative activity and induced dose- and time-dependent increase in the level of nitrites. The investigated molecules significantly decreased cell survival rate, migration capacity and the expression levels of genes included in the process of tumor invasion. Obtained data suggest that the tested hydantoin derivatives express considerable antitumor activity by reducing cell division rate, elevating apoptosis level, and inhibiting the motility and invasiveness of breast cancer cells. The results obtained in this study indicate that investigated compounds express potential as a novel chemotherapeutic agents against breast cancer growth and progression. (C) 2020 The Author(s). Published by Elsevier B.V. on behalf of King Saud University.",
publisher = "Elsevier, Amsterdam",
journal = "Saudi Pharmaceutical Journal",
title = "Antiproliferative and antimigratory effects of 3-(4-substituted benzyl)-5-isopropyl-5-phenylhydantoin derivatives in human breast cancer cells",
pages = "254-246",
number = "3",
volume = "28",
doi = "10.1016/j.jsps.2020.01.003",
url = "conv_472"
}
Obradović, A., Matić, M., Ognjanović, B., Đurđević, P., Marinković, E., Ušćumlić, G., Božić, B.,& Božić-Nedeljković, B.. (2020). Antiproliferative and antimigratory effects of 3-(4-substituted benzyl)-5-isopropyl-5-phenylhydantoin derivatives in human breast cancer cells. in Saudi Pharmaceutical Journal
Elsevier, Amsterdam., 28(3), 246-254.
https://doi.org/10.1016/j.jsps.2020.01.003
conv_472
Obradović A, Matić M, Ognjanović B, Đurđević P, Marinković E, Ušćumlić G, Božić B, Božić-Nedeljković B. Antiproliferative and antimigratory effects of 3-(4-substituted benzyl)-5-isopropyl-5-phenylhydantoin derivatives in human breast cancer cells. in Saudi Pharmaceutical Journal. 2020;28(3):246-254.
doi:10.1016/j.jsps.2020.01.003
conv_472 .
Obradović, Ana, Matić, Miloš, Ognjanović, Branka, Đurđević, Predrag, Marinković, Emilija, Ušćumlić, Gordana, Božić, Bojan, Božić-Nedeljković, Biljana, "Antiproliferative and antimigratory effects of 3-(4-substituted benzyl)-5-isopropyl-5-phenylhydantoin derivatives in human breast cancer cells" in Saudi Pharmaceutical Journal, 28, no. 3 (2020):246-254,
https://doi.org/10.1016/j.jsps.2020.01.003 .,
conv_472 .
3
3
3

The association of circulating sclerostin level with markers of bone metabolism in patients with thyroid dysfunction

Mihaljević, Olgica; Živančević-Simonović, Snežana; Lučić-Tomić, Aleksandra; Živković, Irena; Minić, Rajna; Mijatović-Teodorović, Ljiljana; Jovanović, Zorica; Anđelković, Marija; Stanojević-Pirković, Marijana

(Društvo medicinskih biohemičara Srbije, Beograd i Versita, 2020)

TY  - JOUR
AU  - Mihaljević, Olgica
AU  - Živančević-Simonović, Snežana
AU  - Lučić-Tomić, Aleksandra
AU  - Živković, Irena
AU  - Minić, Rajna
AU  - Mijatović-Teodorović, Ljiljana
AU  - Jovanović, Zorica
AU  - Anđelković, Marija
AU  - Stanojević-Pirković, Marijana
PY  - 2020
UR  - http://intor.torlakinstitut.com/handle/123456789/558
AB  - Background: The aim of this study was to compare serum sclerostin concentrations in patients with thyroid dysfunction with euthyroid control subjects and to assess the relationship between sclerostin and markers of bone metabolism (osteocalcin and beta-cross-laps). Methods: The study included 30 patients with thyroid dysfunction (hypothyroidism, hyperthyroidism and subclinical hyperthyroidism) and ten euthyroid controls. Free thyroxine (FT4) was measured by radioimmunoassay, while thyroid stimulating hormone (TSH) concentration was determined immunoradiometrically. We used an ELISA kit to determine the sclerostin level. The electrochemiluminescence method was applied for measuring the bone markers. Results: Sclerostin levels were significantly lower in hypothyroid patients (p=0.009) and significantly elevated in hyperthyroid patients (p=0.008) compared to control values. Hyperthyroid patients also had higher sclerostin than patients with subclinical hyperthyroidism (p=0.013). Sclerostin concentrations were negatively correlated with TSH levels (r=-0.746, p lt 0.001), but positively with FT4 (r=0.696, p  lt  0.001). Moreover, sclerostin was positively associated with osteocalcin (r=0.605, p=0.005) and beta-cross-laps levels (r=0.573, p=0.008) in all thyroid patients. Conclusions: Serum sclerostin is significantly affected in subjects with thyroid dysfunction. Both sclerostin and thyroid status affect bone homeostasis, which is reflected through the significant correlations with osteocalcin and beta-cross-laps.
AB  - Uvod: Cilj ove studije bio je da uporedimo serumske koncentracije sklerostina kod pacijenata sa disfunkcijom štitaste žlezde u odnosu na eutiroidne kontrolne ispitanike, i da procenimo odnos između sklerostina i markera koštanog metabolizma (osteokalcina i beta-cross-lapsa) u istoj populaciji. Metode: Studijom je obuhvaćeno 30 pacijenata sa disfunkcijom štitaste žlezde (hipotireozom, hipertireozom i supkliničkom hipertireozom) i 10 eutiroidnih kontrola. Slobodni tiroksin (FT4) meren je radioimunološkom metodom, dok je koncentracija tireostimulišućeg hormona (TSH) određivana imunoradiometrijski. Za merenje nivoa sklerostina koristili smo ELISA-test. Metoda elektrohemiluminiscencije primenjena je za merenje koncentracije koštanih markera. Rezultati: Nivo sklerostina bio je značajno niži kod bolesnika sa hipotireozom (p = 0,009) odnosno značajno viši kod bolesnika sa hipertireozom (p = 0,008) u poređenju sa vrednostima kod eutiroidnih kontrolnih ispitanika. Pacijenti sa hipertireozom su takođe imali statistički značajno viši nivo sklerostina u odnosu na bolesnike sa supkliničkom hipertireozom (p = 0,013). Pokazana je negativna korelacija koncentracije sklerostina i TSH (r = -0,746, p  lt  0,001), odnosno pozitivna korelacija sa FT4 (r = 0,696, p  lt  0,001) kod pacijenata sa tireoidnom disfunkcijom. Štaviše, sklerostin pozitivno korelira sa koncentracijom osteokalcina (r = 0,605, p = 0,005) i beta-cross-lapsa (r = 0,573, p = 0,008) kod ovih pacijenata. Zaključak: Serumski nivoi sklerostina izmenjeni su kod osoba sa disfunkcijom štitaste žlezde. Sklerostin zajedno sa tireoidnim statusom utiče na koštani metabolizam, što se ogleda u njegovoj značajnoj korelaciji sa osteokalcinom i beta-cross-lapsom.
PB  - Društvo medicinskih biohemičara Srbije, Beograd i Versita
T2  - Journal of Medical Biochemistry
T1  - The association of circulating sclerostin level with markers of bone metabolism in patients with thyroid dysfunction
T1  - Veza cirkulišućeg nivoa sklerostina sa markerima metabolizma kostiju kod pacijenata sa poremećajem rada štitaste žlezde
EP  - 443
IS  - 4
SP  - 436
VL  - 39
DO  - 10.5937/jomb0-24943
UR  - conv_72
ER  - 
@article{
author = "Mihaljević, Olgica and Živančević-Simonović, Snežana and Lučić-Tomić, Aleksandra and Živković, Irena and Minić, Rajna and Mijatović-Teodorović, Ljiljana and Jovanović, Zorica and Anđelković, Marija and Stanojević-Pirković, Marijana",
year = "2020",
abstract = "Background: The aim of this study was to compare serum sclerostin concentrations in patients with thyroid dysfunction with euthyroid control subjects and to assess the relationship between sclerostin and markers of bone metabolism (osteocalcin and beta-cross-laps). Methods: The study included 30 patients with thyroid dysfunction (hypothyroidism, hyperthyroidism and subclinical hyperthyroidism) and ten euthyroid controls. Free thyroxine (FT4) was measured by radioimmunoassay, while thyroid stimulating hormone (TSH) concentration was determined immunoradiometrically. We used an ELISA kit to determine the sclerostin level. The electrochemiluminescence method was applied for measuring the bone markers. Results: Sclerostin levels were significantly lower in hypothyroid patients (p=0.009) and significantly elevated in hyperthyroid patients (p=0.008) compared to control values. Hyperthyroid patients also had higher sclerostin than patients with subclinical hyperthyroidism (p=0.013). Sclerostin concentrations were negatively correlated with TSH levels (r=-0.746, p lt 0.001), but positively with FT4 (r=0.696, p  lt  0.001). Moreover, sclerostin was positively associated with osteocalcin (r=0.605, p=0.005) and beta-cross-laps levels (r=0.573, p=0.008) in all thyroid patients. Conclusions: Serum sclerostin is significantly affected in subjects with thyroid dysfunction. Both sclerostin and thyroid status affect bone homeostasis, which is reflected through the significant correlations with osteocalcin and beta-cross-laps., Uvod: Cilj ove studije bio je da uporedimo serumske koncentracije sklerostina kod pacijenata sa disfunkcijom štitaste žlezde u odnosu na eutiroidne kontrolne ispitanike, i da procenimo odnos između sklerostina i markera koštanog metabolizma (osteokalcina i beta-cross-lapsa) u istoj populaciji. Metode: Studijom je obuhvaćeno 30 pacijenata sa disfunkcijom štitaste žlezde (hipotireozom, hipertireozom i supkliničkom hipertireozom) i 10 eutiroidnih kontrola. Slobodni tiroksin (FT4) meren je radioimunološkom metodom, dok je koncentracija tireostimulišućeg hormona (TSH) određivana imunoradiometrijski. Za merenje nivoa sklerostina koristili smo ELISA-test. Metoda elektrohemiluminiscencije primenjena je za merenje koncentracije koštanih markera. Rezultati: Nivo sklerostina bio je značajno niži kod bolesnika sa hipotireozom (p = 0,009) odnosno značajno viši kod bolesnika sa hipertireozom (p = 0,008) u poređenju sa vrednostima kod eutiroidnih kontrolnih ispitanika. Pacijenti sa hipertireozom su takođe imali statistički značajno viši nivo sklerostina u odnosu na bolesnike sa supkliničkom hipertireozom (p = 0,013). Pokazana je negativna korelacija koncentracije sklerostina i TSH (r = -0,746, p  lt  0,001), odnosno pozitivna korelacija sa FT4 (r = 0,696, p  lt  0,001) kod pacijenata sa tireoidnom disfunkcijom. Štaviše, sklerostin pozitivno korelira sa koncentracijom osteokalcina (r = 0,605, p = 0,005) i beta-cross-lapsa (r = 0,573, p = 0,008) kod ovih pacijenata. Zaključak: Serumski nivoi sklerostina izmenjeni su kod osoba sa disfunkcijom štitaste žlezde. Sklerostin zajedno sa tireoidnim statusom utiče na koštani metabolizam, što se ogleda u njegovoj značajnoj korelaciji sa osteokalcinom i beta-cross-lapsom.",
publisher = "Društvo medicinskih biohemičara Srbije, Beograd i Versita",
journal = "Journal of Medical Biochemistry",
title = "The association of circulating sclerostin level with markers of bone metabolism in patients with thyroid dysfunction, Veza cirkulišućeg nivoa sklerostina sa markerima metabolizma kostiju kod pacijenata sa poremećajem rada štitaste žlezde",
pages = "443-436",
number = "4",
volume = "39",
doi = "10.5937/jomb0-24943",
url = "conv_72"
}
Mihaljević, O., Živančević-Simonović, S., Lučić-Tomić, A., Živković, I., Minić, R., Mijatović-Teodorović, L., Jovanović, Z., Anđelković, M.,& Stanojević-Pirković, M.. (2020). The association of circulating sclerostin level with markers of bone metabolism in patients with thyroid dysfunction. in Journal of Medical Biochemistry
Društvo medicinskih biohemičara Srbije, Beograd i Versita., 39(4), 436-443.
https://doi.org/10.5937/jomb0-24943
conv_72
Mihaljević O, Živančević-Simonović S, Lučić-Tomić A, Živković I, Minić R, Mijatović-Teodorović L, Jovanović Z, Anđelković M, Stanojević-Pirković M. The association of circulating sclerostin level with markers of bone metabolism in patients with thyroid dysfunction. in Journal of Medical Biochemistry. 2020;39(4):436-443.
doi:10.5937/jomb0-24943
conv_72 .
Mihaljević, Olgica, Živančević-Simonović, Snežana, Lučić-Tomić, Aleksandra, Živković, Irena, Minić, Rajna, Mijatović-Teodorović, Ljiljana, Jovanović, Zorica, Anđelković, Marija, Stanojević-Pirković, Marijana, "The association of circulating sclerostin level with markers of bone metabolism in patients with thyroid dysfunction" in Journal of Medical Biochemistry, 39, no. 4 (2020):436-443,
https://doi.org/10.5937/jomb0-24943 .,
conv_72 .
2
2